PCI Acquires Bellwyck to Expand its Clinical Trial Services

February 12, 2020

The acquisition will bring four new GMP-compliant facilities to the PCI network in the United States, Germany, and Canada.

PCI Pharma Services, a supply chain solutions provider, announced on Feb. 11, 2020 that it is acquiring Bellwyck Pharma Services, a primary and secondary packaging and labeling company for clinical trial and commercial drug markets headquartered in Toronto, Canada.

The acquisition will bring four new GMP-compliant facilities to the PCI network in the United States, Germany, and Canada, which will raise its number of GMP facilities to 25 and its number of employees to over 3700, according to a PCI press release. This acquisition is PCI’s third outside of the US in three years.

“We are delighted that Bellwyck is joining the PCI team and anticipate a seamless integration for our employees and clients. We have a shared focus on innovation, quality, exceptional service, and our employees,” said Jeff Sziklai, CEO, Bellwyck Pharma Services, in the press release. “Joining forces with a global industry leader, such as PCI, is a great step forward for Bellwyck. We look forward to helping accelerate the global growth of PCI’s clinical business, leveraging our reputation for innovative, customized clinical trial solutions for our clients.”

“We are thrilled to welcome the Bellwyck team into the PCI family,” added Salim Haffar, CEO, PCI, in the press release. “Their passion for patients, talented team, and innovative approach to client challenges is perfectly aligned to our purpose and global strategy as PCI strives to be the bridge between life-changing therapies and patients around the world. We are particularly excited that this acquisition will expand our clinical business worldwide and provide our clients with access to sites in continental Europe and Canada, in addition to our existing facilities.”

Source: PCI